icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

India approves AstraZeneca vaccine as company still working on jab’s efficacy of at least 62% after disappointing trial results

India approves AstraZeneca vaccine as company still working on jab’s efficacy of at least 62% after disappointing trial results
India has approved AstraZeneca’s Covid-19 jab for emergency use, despite trials showing its efficacy to be 62 percent with two full shots. AstraZeneca claims to have discovered a new “winning formula,” but hasn’t revealed it yet.

India’s information minister, Prakash Javadekar, announced on Saturday that the coronavirus vaccine, designed by the British-Swedish drugmaker AstraZeneca in collaboration with the University of Oxford, had been approved by regulators a day earlier for emergency use. Formal approval by the Drugs Controller General of India is expected in the coming days.

The news came as India surpassed its 10 millionth case of Covid-19, and inched closer to 150,000 deaths. 

Also on rt.com Argentina 2nd to approve Oxford-AstraZeneca Covid-19 jab, as EU expected to soon follow suit

The vaccine, which will be made locally by the Serum Institute of India, was approved for use in the UK on Tuesday. However, its rollout has been marred by the confusing data on the vaccine’s efficacy against the coronavirus depending on the dosage used, contained in a peer-reviewed study published in The Lancet medical journal last month.

A majority of candidates in AstraZeneca’s trial received two full doses of the vaccine, and for those the jab was found to be 62-percent effective – a number significantly lower than those rival vaccines showed. However, a smaller subgroup was erroneously given a half dose, followed by a full dose – and among these patients, an efficacy rate of 90 percent was reported. Combined, the vaccine’s effectiveness was rated at 70.4 percent. Just over 2,700 participants were given the lower dose, and nobody in this test group was older than 55.

Notably, the Serum Institute had applied for a two-full-dose scheme, which the trials showed to be 62 percent effective. India’s Central Drugs Standard Control Organization (CDSCO) is expected to announce the details in the coming days.

US regulators balked at the disparity in results, and AstraZeneca CEO Pascal Soriot promised a fresh global trial. Last week he told the Sunday Times that his company has discovered a “winning formula” that, after two doses, “is up there with everybody else.”

Also on rt.com Hundreds of Israelis get infected with Covid-19 after receiving Pfizer/BioNTech vaccine – reports

However, Soriot revealed no further details about this formula, saying only that AstraZeneca would publish it “at some point.”

Unlike Pfizer’s mRNA vaccine, the first of its kind to ever be authorized, AstraZeneca’s shot is based on a genetically modified cold virus – a version of a chimpanzee adenovirus – making it cheaper to produce and easier to store under normal refrigeration. This makes distribution easier in less developed countries.

Indian regulators are currently weighing three additional vaccine candidates, including Russia’s Sputnik V. Like AstraZeneca’s offering, Sputnik V is relatively cheap and uses tried-and-tested technology. Unlike the AstraZeneca shot, clinical trials have found Sputnik V to be 91.4-percent effective against Covid-19, and it is based on a well-studied human adenoviral vector-based platform. Ahead of approval, the Russian Direct Investment Fund (RDIF) and Indian generic pharmaceutical company Hetero agreed in November to produce more than 100 million doses of Sputnik V per year on Indian soil.

Also on rt.com Deal with AstraZeneca shames ‘unethical’ attackers of Sputnik V & should inspire cooperation – funder of Russian vaccine tells RT

The Russian manufacturers of Sputnik V also announced last month that they would partner up with AstraZeneca to research the possibility of using both vaccines in a single immunization regimen. Its makers say they are currently working on trials to push the AstraZeneca vaccine’s efficacy above 90 percent.

Think your friends would be interested? Share this story!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.

Podcasts